Search

ACADIA Pharmaceuticals Inc

Cerrado

SectorSanidad

27.11 -0.95

Resumen

Variación precio

24h

Actual

Mínimo

26.64

Máximo

27.29

Métricas clave

By Trading Economics

Ingresos

32M

35M

Ventas

40M

308M

P/B

Media del Sector

12.341

56.432

BPA

0.18

Margen de beneficios

11.41

Empleados

796

EBITDA

25M

32M

Recomendaciones

By TipRanks

Recomendaciones

Comprar

Estimación a 12 Meses

+29.82% upside

Dividendos

By Acuity

Próximas Ganancias

4 nov 2026

Estadísticas de Mercado

By TradingEconomics

Capitalización Mercado

356M

4.7B

Apertura anterior

28.06

Cierre anterior

27.11

Noticias sobre sentimiento de mercado

By Acuity

50%

50%

115 / 339 Clasificación en Healthcare

ACADIA Pharmaceuticals Inc Gráfico

Resultados pasados no son un indicador fiable de resultados futuros.

Noticias Relacionadas

18 sept 2026, 22:46 UTC

ACADIA Pharmaceuticals Inc is down in after-market trading, following earlier losses, and remains below its 20-day moving average amid stagnant U.S. industrial production.

17 sept 2026, 19:36 UTC

ACADIA Pharmaceuticals Inc shares fell sharply, pulling back from an early high and remaining 4.38% below its 20-day moving average.

16 sept 2026, 19:16 UTC

ACADIA Pharmaceuticals Inc shares are higher, reaching a notable peak in early afternoon, despite trading below its 20-day moving average.

14 sept 2026, 20:08 UTC

ACADIA Pharmaceuticals Inc shares are lower today, reflecting broader market declines amid rising crude oil prices and inflation concerns ahead of the Federal Reserve's decision.

9 sept 2026, 20:07 UTC

ACADIA Pharmaceuticals Inc shares are higher Wednesday, pulling back earlier in the session. Broader market context includes rising crude oil prices above $100.

8 sept 2026, 20:01 UTC

News

ACADIA Pharmaceuticals is lower today, driven by significant declines in the Biotechnology sub-sector, reversing recent higher closes since Friday.

3 sept 2026, 20:02 UTC

Social Media

ACADIA Pharmaceuticals shares are declining, despite Canaccord Genuity and UBS reiterating Buy ratings and raising price targets amid positive outlooks for its products.

2 sept 2026, 20:08 UTC

ACADIA Pharmaceuticals is higher today, driven by gains in biotechnology stocks. Earlier, the stock peaked above Tuesday's close before pulling back slightly.

1 sept 2026, 20:09 UTC

ACADIA Pharmaceuticals is lower in Tuesday trading, in line with broader market declines amid rising oil prices and increasing Treasury yields.

31 ago 2026, 21:01 UTC

ACADIA Pharmaceuticals is higher in after-market trading, reflecting a notable move since Monday's close amid broader market sentiment on potential interest rate hikes.

28 ago 2026, 20:07 UTC

News

ACADIA Pharmaceuticals received EU approval for DAYBU to treat Rett syndrome. Shares are declining despite this development, reflecting unusual volatility during Friday's session.

27 ago 2026, 23:41 UTC

ACADIA Pharmaceuticals shares are trading lower in after-market hours, despite being above the 20-day moving average and near the upper end of its trading range.

26 ago 2026, 20:08 UTC

ACADIA Pharmaceuticals is trading lower amid a weaker market following inflation data that may influence future Federal Reserve policy decisions.

25 ago 2026, 20:07 UTC

News
Event

Analysts' upgrades boost ACADIA Pharmaceuticals, with Deutsche Bank raising its price target to $38 and Citigroup to $40 following DAYBUE's EU approval.

24 ago 2026, 20:06 UTC

News
Event

ACADIA Pharmaceuticals received European Commission approval for DAYBU, the first treatment for Rett syndrome in the EU. Shares are advancing during Monday's session.

21 ago 2026, 19:56 UTC

ACADIA Pharmaceuticals shares are higher, recovering from an early dip. The move aligns with broader market trends following a surge in Bitcoin prices.

20 ago 2026, 20:01 UTC

ACADIA Pharmaceuticals shares are lower amid a broader decline in biotechnology stocks, with unusual volatility noted today and cumulative returns down since Wednesday.

19 ago 2026, 19:46 UTC

ACADIA Pharmaceuticals is trading higher, reflecting positive sentiment in the biotechnology sector amid declining bond yields and increased liquidity, despite a recent pullback.

18 ago 2026, 20:02 UTC

News

BMO maintained an Outperform rating on ACADIA Pharmaceuticals with a $36 price target, contributing to positive market sentiment and advancing shares today.

17 ago 2026, 23:06 UTC

ACADIA Pharmaceuticals shares are trading higher in after-market hours, maintaining a gain while above their 20-day moving average and near a one-month high.

13 ago 2026, 20:01 UTC

ACADIA Pharmaceuticals Inc shares are lower today, continuing a decline from Wednesday's close. No specific news was identified to explain the movement.

12 ago 2026, 19:56 UTC

News

Needham maintained its Buy rating on ACADIA Pharmaceuticals and raised the price target to $41. Shares are trading higher since Tuesday's close.

11 ago 2026, 19:36 UTC

ACADIA Pharmaceuticals remains near unchanged amid broader market sentiment influenced by geopolitical tensions and upcoming U.S. inflation reports affecting interest rate policy.

7 ago 2026, 20:06 UTC

ACADIA Pharmaceuticals Inc shares are advancing, maintaining a strong position above the 20-day moving average and near the upper end of their one-month range.

6 ago 2026, 23:41 UTC

ACADIA Pharmaceuticals shares are higher in after-market trading, reflecting strong performance above its 20-day moving average and nearing the upper end of its one-month range.

5 ago 2026, 20:02 UTC

News

ACADIA Pharmaceuticals shares rise following strong Q2 results and positive analyst ratings, with revenue guidance increased to $1.24 billion to $1.30 billion.

4 ago 2026, 23:01 UTC

News

Acadia Pharmaceuticals shares are higher after reporting strong Q2 results, with GAAP net sales of DAYBUE reaching $125 million and raising full-year revenue guidance.

3 ago 2026, 21:01 UTC

ACADIA Pharmaceuticals Inc shares are lower in after-market trading, continuing a trend of three consecutive sessions finishing lower without any specific news identified.

31 jul 2026, 20:03 UTC

ACADIA Pharmaceuticals shares are lower today, continuing a decline since Thursday's close. Rising Treasury yields and crude oil prices contribute to inflation concerns.

30 jul 2026, 19:58 UTC

ACADIA Pharmaceuticals shares are higher, reflecting a broader recovery in tech stocks amid improving market sentiment and bargain hunting after recent sell-offs.

Comparación entre iguales

Cambio de precio

ACADIA Pharmaceuticals Inc previsión

Precio Objetivo

By TipRanks

29.82% repunte

Estimación a 12 Meses

Media 35.429 USD  29.82%

Máximo 49 USD

Mínimo 25 USD

De acuerdo con 15 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para ACADIA Pharmaceuticals Inc Dist en los últimos 3 meses.

Consenso

By TipRanks

Comprar

15 ratings

11

Comprar

4

Mantener

0

Vender

Sentimiento

By Acuity

115 / 339 Clasificación en Sanidad

Noticias sobre sentimiento de mercado

Neutral

Volatilidad

Por debajo de la media

Volumen de Noticias (RCV)

Por debajo de la media

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

$

Acerca de ACADIA Pharmaceuticals Inc

ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization innovative medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases in the United States. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; and DAYBUE, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 for treatment of Rett Syndrome. It also develops Pimavanserin that is in Phase III ADVANCE-2 study to treat the negative symptoms of schizophrenia; ACP-101 whixh is in Phase III for the treatment of hyperphagia in Prader-Willi syndrome; ACP-204 which is in Phase II for the treatment of Alzheimer's disease psychosis; ACP-2591 that is in Phase I for Rett syndrome and Fragile X syndrome; preclinical antisense oligonucleotide programs; and other programs for neuropsychiatric symptoms. It has a license agreement with Neuren Pharmaceuticals Limited to develop and commercialize trofinetide for Rett syndrome and other indications; and a license and collaboration agreement with Stoke Therapeutics, Inc. to discover, develop and commercialize novel RNA-based medicines for the potential treatment of severe and rare genetic neurodevelopmental diseases of the CNS. The company was formerly known as Receptor Technologies, Inc. and changed its name ACADIA Pharmaceuticals Inc. in 1997. ACADIA Pharmaceuticals Inc. was incorporated in 1993 and is headquartered in San Diego, California.